Bio-Techne Corporation (TECH), headquartered in Minneapolis, Minnesota, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets. Valued at $11.4 billion by market cap, the company specializes in proteins, cytokines, growth factors, immunoassays and small molecules.
Shares of this leading life sciences reagents and instruments company have outperformed the broader market over the past year. TECH has gained 25.1% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 10.7%. In 2026, TECH stock is up 23.7%, surpassing the SPX’s 7% rise on a YTD basis.
Zooming in further, TECH’s outperformance is also apparent compared to the iShares Biotechnology ETF’s (IBB). The exchange-traded fund has gained about 23.4% over the past year. Moreover, TECH’s gains on a YTD basis outshinethe ETF’s 21.7% returns over the same time frame.
Bio-Techne has outperformed primarily due to the June 25 announcement that Merck KGaA (MKKGY) agreed to acquire the company for $73 per share in cash (an enterprise value of roughly $11.3 billion), which re-rated the stock toward the buyout price following a spring pullback near its 52-week low. Prior to and alongside that catalyst, operational improvements, including higher GAAP operating margins, cost/profitability initiatives, portfolio pruning such as the Exosome Diagnostics divestiture, and stabilization in core research and diagnostics demand, helped support earnings recovery, while subsequent antitrust clearances and shareholder approval kept the shares trading near the $73 deal price.
On Nov. 6, TECH shares closed up marginally after reporting its Q1 results. Its revenue stood at $299.7 million, up 4.6% year over year. The company’s adjusted EPS increased 4.8% from the year-ago quarter to $0.44.
For the current fiscal year, ending in June 2027, analysts expect TECH’s EPS to grow 1.7% to $1.75 on a diluted basis. The company’s earnings surprise history is mixed. It beat or matched the consensus estimate in three of the last four quarters while missing the forecast on another occasion.
Among the 13 analysts covering TECH stock, the consensus is a “Hold.” That’s based on one “Strong Buy” rating, 11 “Holds,” and one “Strong Sell.”
The configuration has been relatively stable over the past three months.
On Nov. 10, Evercore Inc. (EVR) maintained a “Hold” rating on TECH, with a price target of $73, implying a marginal potential upside from current levels.
While TECH currently trades above its mean price target of $71.10, the Street-high price target of $77 suggests an upside potential of 5.8%.